Courier Capital LLC Has $2.90 Million Stake in Eli Lilly and Company (NYSE:LLY)

Courier Capital LLC trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 7.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,971 shares of the company’s stock after selling 382 shares during the period. Courier Capital LLC’s holdings in Eli Lilly and Company were worth $2,898,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Simon Quick Advisors LLC boosted its position in Eli Lilly and Company by 10.5% during the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after acquiring an additional 278 shares during the last quarter. Liontrust Investment Partners LLP bought a new stake in Eli Lilly and Company during the third quarter valued at $8,326,000. Armstrong Fleming & Moore Inc bought a new stake in Eli Lilly and Company during the second quarter valued at $357,000. Redhawk Wealth Advisors Inc. boosted its position in Eli Lilly and Company by 0.9% during the third quarter. Redhawk Wealth Advisors Inc. now owns 6,986 shares of the company’s stock valued at $3,752,000 after acquiring an additional 65 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in Eli Lilly and Company by 4.0% during the third quarter. Assenagon Asset Management S.A. now owns 474,940 shares of the company’s stock valued at $255,105,000 after acquiring an additional 18,079 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $778.69 on Thursday. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The stock has a market cap of $739.88 billion, a price-to-earnings ratio of 134.26, a PEG ratio of 1.70 and a beta of 0.34. Eli Lilly and Company has a fifty-two week low of $334.58 and a fifty-two week high of $800.78. The firm’s 50-day simple moving average is $727.96 and its 200 day simple moving average is $636.01.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter last year, the business posted $2.09 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which is available at this link. In the last 90 days, insiders sold 195,055 shares of company stock worth $125,254,657. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Truist Financial reaffirmed a “buy” rating and set a $850.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 22nd. BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Wells Fargo & Company increased their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $689.52.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.